Earnings summaries and quarterly performance for AbCellera Biologics.
Executive leadership at AbCellera Biologics.
Board of directors at AbCellera Biologics.
Research analysts who have asked questions during AbCellera Biologics earnings calls.
MH
Malcolm Hoffman
BMO Capital Markets
4 questions for ABCL
Also covers: ACAD, BMY, BNTX +2 more
BS
Brendan Smith
Stifel, Nicolaus & Company, Incorporated
3 questions for ABCL
Also covers: ABSI, ARWR, AZTA +19 more
AN
Andrea Newkirk
Goldman Sachs
2 questions for ABCL
Also covers: ALKS, ARWR, DAWN +9 more
AT
Andrea Tan
Goldman Sachs
2 questions for ABCL
Also covers: ARWR, DAWN, INSM +3 more
Faisal Khurshid
Leerink Partners
2 questions for ABCL
Also covers: ANIP, GERN, GLPG +4 more
PS
Puneet Souda
Leerink Partners
2 questions for ABCL
Also covers: A, BRKR, CSTL +20 more
SD
Srikripa Devarakonda
Truist Financial Corporation
2 questions for ABCL
Also covers: ABSI, AFMD, ARVN +12 more
SW
Stephen Willey
Stifel Financial Corp.
2 questions for ABCL
Also covers: CELC, CGEN, CUE +10 more
Allison Bratzel
Piper Sandler Companies
1 question for ABCL
Also covers: AKBA, ALXO, ARDX +5 more
Conor MacKay
BMO Capital Markets
1 question for ABCL
Also covers: AMGN, ARVN, INCY
DM
David Martin
Bloom Burton & Co.
1 question for ABCL
Also covers: AUPH
JK
Jacqueline Kisa
TD Cowen
1 question for ABCL
Also covers: DNA, OABI
KD
Kripa Devarakonda
Truist Securities
1 question for ABCL
Also covers: ARVN, BMY, INCY +5 more
MA
Micheal Almisry Sonntag
Leerink Partners
1 question for ABCL
SW
Stephen Willey
Stifel
1 question for ABCL
Also covers: ABEO, CGEN, CMPX +7 more
SD
Steve Dechert
KeyBanc Capital Markets
1 question for ABCL
Also covers: ABSI, CERT, LFMD +2 more
Recent press releases and 8-K filings for ABCL.
AbCellera Biologics Provides Pipeline Update and Strategic Shift at J.P. Morgan Healthcare Conference
ABCL
New Projects/Investments
Guidance Update
- AbCellera Biologics reported approximately $680 million in total liquidity as of the end of Q3 2025 and has completed significant infrastructure investments, including a new GMP manufacturing facility that began engineering runs in December 2025.
- The company has strategically shifted its business model from primarily discovery partnerships to internal pipeline development, a decision made in September 2023, focusing on creating first-in-class and highly differentiated molecules.
- Its lead asset, AbCell 635, an antibody for non-hormonal treatment of menopausal vasomotor symptoms, has advanced to Phase 2 of a Phase 1-2 study, with a significant data readout anticipated in Q3 2026.
- Other key pipeline updates include AbCell 575 in Phase 1, with a readout expected near the end of 2026, and new development candidates AbCell 386 (oncology) and AbCell 688 (autoimmune) in IND-enabling work. The company plans to nominate one additional candidate in 2026.
Jan 14, 2026, 11:45 PM
AbCellera Biologics Provides Pipeline and Strategic Updates at JPMorgan Healthcare Conference
ABCL
New Projects/Investments
Product Launch
- AbCellera Biologics reported a strong liquidity position with approximately $680 million as of the end of Q3.
- The company is actively transitioning its business model from a partnership-focused platform to an internal clinical development company, a strategic decision made in September 2023.
- Its lead asset, AbCell 635, a first-in-class antibody for vasomotor symptoms, has progressed to Phase 2 of a Phase 1-2 study, with a significant data readout anticipated in Q3 2026.
- AbCellera has also advanced AbCell 575 into Phase 1 (with a readout expected near the end of 2026) and nominated two new development candidates, AbCell 386 (oncology) and AbCell 688 (autoimmune conditions), which are currently in IND-enabling work.
- The company has completed its platform investments, including a new GMP manufacturing facility that began engineering runs in December 2025 and is now manufacturing products for its pipeline.
Jan 14, 2026, 11:45 PM
AbCellera Biologics Provides Update on Pipeline Progress and Financial Position
ABCL
New Projects/Investments
Guidance Update
- AbCellera reported a strong liquidity position of approximately $680 million as of the end of Q3, supported by $1.5 billion in non-dilutive funding, including $1 billion in royalty revenue from its COVID-19 partnership with Eli Lilly.
- The company's lead asset, ABCL635, for non-hormonal treatment of menopausal vasomotor symptoms, has progressed to Phase II, with a significant data readout anticipated in Q3 2026.
- AbCellera is transitioning to internal pipeline development, with its newly operational GMP manufacturing facility supporting the advancement of its assets, including ABCL575 (Phase I readout by end of 2026) and new candidates ABCL386 (oncology) and ABCL688 (autoimmune).
Jan 14, 2026, 11:45 PM
AbCellera Announces First Patients Dosed in Phase 2 of ABCL635 Clinical Trial
ABCL
New Projects/Investments
Product Launch
- AbCellera announced on January 12, 2026, that the first patients have been dosed in the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635.
- ABCL635 is a potential first-in-class non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause.
- The company anticipates top-line clinical results for both phases in Q3 2026.
Jan 14, 2026, 10:09 PM
ABCL provides updates on pipeline progress and 2025-2026 priorities
ABCL
New Projects/Investments
Guidance Update
- ABCL, a clinical-stage biotech company, reported approximately $680M in available liquidity as of September 30, 2025.
- In 2025, the company initiated ABCL635 Phase 1/2 (June 2025) and ABCL575 Phase 1 (July 2025) clinical trials, and nominated two additional development candidates, ABCL688 and ABCL386, for IND-enabling activities.
- Key 2026 priorities include topline readouts in H2 2026 for both ABCL635 and ABCL575 Phase 1 clinical trials.
- ABCL635, a potential first-in-class antibody for the non-hormonal treatment of vasomotor symptoms (VMS), is currently in a Phase 2 clinical trial with results anticipated in Q3 2026.
Jan 14, 2026, 12:00 PM
AbCellera Biologics Details Transition to Clinical-Stage Biotech and Pipeline Strategy
ABCL
New Projects/Investments
Product Launch
- AbCellera Biologics is transitioning from a platform-focused company to a clinical-stage biotech, having completed investments in downstream capabilities, including a clinical manufacturing facility in Vancouver, to support its internal pipeline.
- The company has shifted its strategy to prioritize internal programs, stopping active pursuit of new partnerships while maintaining existing commitments and selectively considering new ones that align with internal criteria.
- Its most advanced internal program, ABCL635, is a non-hormonal treatment for moderate to severe hot flashes, currently in a Phase I trial to assess efficacy signals and target engagement.
- AbCellera also has ABCL575 for atopic dermatitis, which it aims to partner after Phase I data, and ABCL688 for autoimmune conditions, with an IND or Canadian equivalent CTA submission expected in mid-2026.
- The company maintains a strong capital position with approximately $680 million in available liquidity at the end of the last quarter, providing a runway of well over three years for continued investment in its internal pipeline.
Dec 3, 2025, 1:00 PM
AbCellera Biologics Discusses Transition to Clinical Stage and Pipeline at Piper Sandler Conference
ABCL
New Projects/Investments
- AbCellera Biologics has transitioned from a platform-focused company to a clinical-stage biotech, having completed investments to build end-to-end integrated capabilities from target assessment to clinical manufacturing.
- The company is advancing its internal pipeline, with ABCL635 (non-hormonal treatment for hot flashes) as its most advanced program, currently in a Phase 1 trial. ABCL688, targeting autoimmune conditions, is expected to have an IND/CTA submission in mid-2026.
- AbCellera has stopped actively seeking new partnerships to prioritize independent drug development, though it remains committed to existing partners and may selectively accept new programs.
- The company maintains a strong capital position with approximately $680 million in available liquidity as of the end of the last quarter, providing over three years of runway for internal pipeline investments.
Dec 3, 2025, 1:00 PM
AbCellera Details Transition to Clinical-Stage Biotech and Pipeline Programs
ABCL
New Projects/Investments
Guidance Update
- AbCellera (ABCL) has transitioned from a platform-focused company to a clinical-stage biotech, having completed investments in downstream capabilities for translational biology, manufacturing, and clinical development, making it end-to-end integrated.
- The company has stopped actively seeking new partnerships to prioritize its internal pipeline but remains committed to existing collaborations and may selectively accept new programs that align with its strategic focus.
- ABCL's most advanced internal program, ABCL 635, is in a Phase 1 trial for the non-hormonal treatment of moderate to severe hot flashes (vasomotor symptoms), targeting NK3R, with early efficacy signals expected from the study.
- ABCL 575, an OX40 ligand blocker for atopic dermatitis, is also in Phase 1, with the company seeking to confirm its safety and pharmacokinetic/pharmacodynamic profile to potentially partner the program for further development.
- AbCellera maintains a strong capital position with approximately $680 million in available liquidity as of the end of the last quarter, providing over three years of funding for its internal pipeline, which includes ABCL 688 (autoimmune conditions) and over 20 other programs.
Dec 3, 2025, 1:00 PM
AbCellera Biologics Discusses Clinical Pipeline Transition and Financial Position
ABCL
New Projects/Investments
Guidance Update
- AbCellera Biologics has completed its transition to developing its own clinical assets, with its first two wholly-owned assets moving into the clinic in 2025.
- The lead wholly-owned asset, ABCL635, an antibody against the NK3R receptor for hot flashes associated with VMS, is in Phase 1 trials, with proof-of-concept data expected by mid-2026. This asset is differentiated as a first-in-class monoclonal antibody with a potential monthly injectable dosing regimen.
- Other pipeline assets include ABCL575, an OX40 ligand antagonist in Phase 1, and ABCL688, a new IND candidate targeting GPCRs, which entered IND-enabling studies in Q3 2025.
- The company reports a strong balance sheet with over CAD 500 million in cash and equivalents and just under CAD 200 million in available liquidity from government funding, totaling around CAD 700 million in liquidity, sufficient for at least the next three years.
Nov 13, 2025, 1:00 PM
AbCellera Provides Update on Clinical Pipeline and Financial Position
ABCL
New Projects/Investments
Guidance Update
- AbCellera has transitioned to developing its own clinical assets, with two wholly-owned assets, ABCL635 and ABCL575, entering the clinic in Q2 2025, and a third, ABCL688, in IND enabling studies in Q3 2025. The company expects first readouts for its wholly-owned assets in 2026.
- ABCL635, an antibody for hot flashes associated with VMS, is a first-in-class monoclonal antibody with potential for monthly subcutaneous injection. Phase 1 includes a proof of concept study in post-menopausal women, with biomarker data and proof of concept results expected by mid-2026.
- As of its Q3 earnings, AbCellera reported the following liquidity information :
| Metric | Q3 2025 |
|---|---|
| Cash and Equivalents ($USD Millions) | Over $500 |
| Available Liquidity from Government Spending ($USD Millions) | Under $200 |
| Total Available Liquidity ($USD Millions) | Around $700 |
| Liquidity Runway (Years) | At least 3 |
Nov 13, 2025, 1:00 PM
Quarterly earnings call transcripts for AbCellera Biologics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more